PYC Therapeutics (ASX:PYC) reported Thursday that its loss per diluted share in the fiscal first half widened to AU$0.0549, from a loss of AU$0.04 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting a diluted loss per share of AU$0.03.
Revenue for the six months ended Dec. 31, 2024, was AU$12.7 million, up 39% from AU$9.1 million in the same period last year. Analysts surveyed by Visible Alpha expected AU$11.4 million in total revenue.
Analysts polled by Visible Alpha expect earnings of AU$0.10 per diluted share on revenue of AU$18.7 for the full fiscal year.
The firm did not pay or declare any dividends during the period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。